Rigel Pharmaceuticals (RIGL) risk factors
Item 1A of every Rigel Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors59 risks9 new9 dropped21 reworded
Rigel expanded commercial operations with REZLIDHIA for R/R AML and settled Annora generic litigation for TAVALISSE. The company faced increased scrutiny on pricing methodologies and drug rebate reporting compliance. Regulatory hurdles grew with new EU health technology assessment regulations and UK orphan drug rules.
Filed Mar 03, 2026 - FY2024 10-K risk factors59 risks
Rigel faces intense pharmaceutical competition, patent challenges for TAVALISSE, and capital dilution risks. The company relies heavily on third-party distributors and collaborative partnerships for pipeline expansion. Strict regulatory compliance, pricing pressures, and future funding needs dominate the operational landscape.
Filed Mar 04, 2025